Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL28569951 | 0.98 | CA9 (0.77) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL521524 | 0.89 | CA9 (1.00) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL29370621 | 0.89 | CA9 (1.00) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL519951 | 0.86 | CA9 (0.59) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL31231828 | 0.86 | CA9 (0.59) | CA9MAPTKDM4EMEN1GAA | |
| Methane SCHEMBL28577463 | 0.84 | CA9 (0.57) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL7505614 | 0.80 | MAPT (0.59) | CA9MAPTKDM4EMEN1KMT2A | |
| SCHEMBL30468520 | 0.79 | CA9 (0.70) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL398137 | 0.79 | CA9 (0.70) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL2913394 | 0.79 | CA9 (0.51) | CA9MAPTKDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | claimed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | claimed |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | US | claimed |
| EP-2268144-A2 | DIAMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | Bayer CropScience AG (DE) | 2011-01-05 | — | — | EP | claimed |
| US-20100081679-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-04-01 | — | — | US | claimed |
| WO-2010025871-A1 | 4-HALOGEN ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES FOR USE AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2161259-A1 | 4-Haloalkyl substituted Diaminopyrimidine | Bayer CropScience AG (DE) | 2010-03-10 | — | — | EP | claimed |
| EP-2129222-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | Bayer CropScience AG (DE) | 2009-12-09 | — | — | EP | claimed |
| WO-2009115267-A2 | DIAMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AG (DE) | 2009-09-24 | — | — | WO | claimed |
| WO-2008107096-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2008-09-12 | — | — | WO | claimed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-4963677-A | TREATMENT OF CONGESTIVE HEART FAILURE | ORION CORPORATION LTD. (FI) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | CA9 2850/4885MAPT 1028/4885KDM4E 1934/4885 |
| US-20100081679-A1 | DIAMINOPYRIMIDINES AS FUNGICIDES | PM20D2, DDT, DDX41 | CA9 707/4885MAPT 4391/4885KDM4E 1075/4885 |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | CA9 2561/4885MAPT 4144/4885KDM4E 1081/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | CA9 2850/4885MAPT 1028/4885KDM4E 1934/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | CA9 2850/4885MAPT 1028/4885KDM4E 1934/4885 |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | CA9 4668/4885MAPT 2086/4885KDM4E 3667/4885 |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | DDX41, DDX1, DDX5 | CA9 1421/4885MAPT 4235/4885KDM4E 2179/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CA9 4678/4885MAPT 438/4885KDM4E 1645/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | CA9 2906/4885MAPT 3484/4885KDM4E 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.